CD8A and neoplasm: In addition, the CXCR2 antagonist can reduce PMN-MDSC accumulation, increase CD8 T cell infiltration in the tumor, and further enhance the efficacy of anti-PD-1 in tumor-bearing mice (Zhou et al., 2022).